Clinical Trial Update: Tecarfarin Anti-Coagulation Trial (TACT) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Tecarfarin in anticoagulation (TACT) investigating prevention of thromboembolism and thrombosis. Status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboembolism
• Thrombosis

Drugs mentioned

• Tecarfarin (tecarfarin)

Snippet

Sponsor: Espero Biopharma | Conditions: Thromboembolism, Thrombosis | Phase 3 | Status: UNKNOWN